This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Murray, K. F. Search for Related Content PubMed PubMed Citation Articles by Murray, K. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB RIBAVIRIN Social Bookmarking                         What's this?

Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection

Division of Gastroenterology and Nutrition, Department of Pediatrics, University of Washington, Children's Hospital and Regional Medical Center, Seattle, Washington, USA, Karen.murray{at}seattlechildrens.org

James R. Rodrigue

The Transplant Center, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Regino P. González-Peralta

Section of Hepatology and Liver Transplantation, Department of Pediatrics, University of Florida, Gainesville, Florida, USA

John Shepherd

Department of Radiology, University of California, San Francisco, California, USA

Bruce A. Barton

Maryland Medical Research Institute, Baltimore, Maryland, USA

Patricia R. Robuck

Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland, USA

Kathleen B. Schwarz

Division of Pediatric Gastroenterology and Nutrition, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

for the PEDS-C Clinical Research Network

Background PEDS-C is the first multicenter placebo-controlled trial for the treatment of chronic hepatitis C (HCV) in childhood that has ever been conducted in the United States (USA). Establishment of the research team, protocol, administrative infrastructure, and ancillary contributors for the pediatric trial took years of planning.

Purpose To study the safety and efficacy of pegylated-interferon alpha (PEG-2a) plus ribavirin (RV) with PEG-2a monotherapy in children aged 5 years through 18 years. To assess the health-related quality of life and growth and body composition in children with chronic hepatitis C infection, before, during, and after treatment. Methods Eleven centers of pediatric hepatobiliary clinical research were united in a National Institutes of Diabetes and Digestive and Kidney Diseases (NIDDK) funded grant with financial support from the Food and Drug Administration (FDA) and a corporate sponsor to conduct the treatment trial.

Limitations The most important initial limitation in the design of this complex study was securing the financial support and infrastructural organization, a process that took several years. Challenges faced by the study group included identifying the optimal study design given the limited study population, and determining what ancillary studies could be incorporated into the treatment trial.

Conclusions In this article the process taken to design the study and administrative infrastructure, the lessons learned, and the controversial issues deliberated during the planning process are discussed. The evolution of the study and the considerations taken in the development of the protocol are valuable tools which can be applied to pediatric clinical trials in general. Clinical Trials 2007; 4: 661—673. http://ctj.sagepub.com

References

• Badizadegan K., Jonas MM, Ott MJ, et al. Histopathology of the liver in children with chronic hepatitis C viral infection. Hepatology 1998; 28(5): 1416—23.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rosenthal P. Chronic hepatitis C viral infection in childhood: to treat or not to treat with interferon-that is the question. J Pediatr Gastroenterol Nutr 1997; 23: 363—64.
• Fried M., Hoofnagle J. Therapy of hepatitis C. Semin Liver Dis 1995; 15(1): 82—91.[Web of Science][Medline] [Order article via Infotrieve]
• Pensati P., Iorio R., Botta S., et al. Low virological response to interferon in children with chronic hepatitis C. J Hepatol 1999; 31: 604—11.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jacobson KR, Murray K., Zellos A., Schwarz KB An analysis of published trials of Interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 2002; 34(1): 52—58.[Web of Science][Medline] [Order article via Infotrieve]
• Willhite CC, Ferm VH Potentiation of ribavirin-induced teratogenesis by natural purines. Exp Mol Pathol 1978; 28: 196—201.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ferm VH, Willhite CC, Kilham L. Teratogenic effects of ribavirin on hamster and rat embryos. Teratol 1978; 17: 93—102.[CrossRef]
• Kochar DM, Penner JD, Knudsen TB Embryotoxic, teratogenic, and metabolic effects of Ribavirin in mice. Toxicol Appl Pharmacol 1980; 52: 99—112.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Agnish, MD. An oral gavage study for effects of RO 20—9963 (Ribavirin) on fertility and early embryonic development to implantation in Sprague dawley rats (Covance Study No 6131—316, Roche Study No 07392) RR 1003508.
• Zeuzem S., Feinman SV, Rasenack J., et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med 2000; 343: 1666—72.[Abstract/Free Full Text]
• Comanor L., Minor J., Conjeevaram HS, et al. Impact of chronic hepatitis B and interferon-a therapy on growth of children. J Viral Hepatitis 2001; 8: 139—47.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gottrand F., Michaud L., Guimber D., et al. Influence of recombinant interferon alpha on nutritional status and growth pattern in children with chronic viral hepatitis. Eur J Pediatr 1996; 155: 1031—34.[Web of Science][Medline] [Order article via Infotrieve]
• Briend A., Garenne M., Maire B., et al. Nutritional status, age, and survival: the muscle mass hypothesis. Eur J Clin Nutr 1989; 43: 715—26.[Web of Science][Medline] [Order article via Infotrieve]
• Davis GL, Esteban-Mur R., Rustgi V., et al. Interferon alfa-2b alone of in combination with ribavirin for the treatment of relapse of chronic hepatitis C. New England J Med 1998; 339(21): 1493—99.[Abstract/Free Full Text]
• McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New England Journal of Medicine 1998; 339(21): 1485—92.[Abstract/Free Full Text]
• Poynard T., Marcellin P., Lee S., et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998; 352: 1426—32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Manns MP, McHutchison JC, Gordon SC, et al. Pegilated interferon lafa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958—965.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fried M., Shiffman M., Reddy K., et al. Peginterferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Eng J Med 2002; 347: 975—82.[Abstract/Free Full Text]
• Malek-Ahmadi P. Mood disorders associated with interferon treatment: theoretical and practical considerations. Ann Pharmacother 2001; 35: 489—95.[Abstract]
• Musselman D., Lawson D., Gumnick J., et al. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344: 961—6.[Abstract/Free Full Text]
• Bonaccorso S., Marino V., Puzella A., et al. Increased depressive ratings in patients with hepatitis C receiving interferon-alpha-based immunotherapy are related to interferon-alpha-induced changes in the serotonergic system. J Clin Psychopharmacol 2002; 22: 86—90.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bagheri H., Fouladi A., Barange K., et al. Follow-up of adverse drug reactions from peginterferon alfa-2b-ribavirin therapy. Pharmacotherapy 2004; 24: 1546—53.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Raison C., Borisov A., Broadwell S., et al. Depression during pegylated interferon-alpha plus ribavirin therapy: Prevalence and prediction. J Clin Psychiatry 2005; 66: 41—8.[Web of Science][Medline] [Order article via Infotrieve]
• Kraus M., Schafer A., Csef H., Scheurlen M. Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C. World J Gastroenterol 2005; 11: 1769—74.[Medline] [Order article via Infotrieve]
• González-Peralta RP, Kelly DA, Haber B., et al. Nterferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 2005.
• Corporation S. Medical Economics 2002; 3153—57.
• Bonkovsky HL, Woolley JM Reduction of healthrelated quality of life in chronic hepatitis C and improvement with interferon therapy: The Consensus Interferon Study Group. Hepatology 1999; 29: 264—70.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002; 35: 433—9.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Obhrai J., Hall Y., Anand BS Assessment of fatigue and psychologic disturbances in patients with hepatitis C virus infection. J Clin Gastroenterol. 2001; 32: 413—7.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Spiegel, BMR, Younossi, ZM, Hays, RD et al. Impact of hepatitis C on health-related quality of life: a systematic review and quantitative assessment. 2005; 41: 790—800.
• Posthouwer D., Plug I., van der Bom JG, et al. Hepatitis C and health-related quality of life among patients with hemophilia. Haematologica 2005; 90: 846—50.[Abstract/Free Full Text]
• Schwarz KB, Mohan P., Narkewicz M., et al. The Safety, Efficacy and Pharmacokinetics of Peginterferon Alpha-2a (40KD) in Children with Chronic Hepatitis C. Gastroenterology 2003; 124: 4(Suppl 1): A700.
• Wirth S., Pieper-Boustani H., Lang T., et al. Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 2005; 41(5): 1013—1018.[CrossRef][Web of Science]
• Zein NN, Rakela J., Krawitt EL, et al. Hepatitis C Virus Genotypes in the United States: Epidemiology, Pathogenicity, and Response to Interferon Therapy. Annals of Internal Medicine 1996; 125(8): 634—9.[Abstract/Free Full Text]
• Herrine SK, Rossi S., Navarro VJ Management of patients with chronic hepatitis C infection. Clin Exp Med 2006; 6: 20—26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Reynolds WM, Anderson G., Bartell N. Measuring depression in children: A multimethod assessment investigation. J Abnorm Child Psychol 1985; 13: 513—26.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Association, AP Quick reference to the Diagnostic Criteria from DSM-IV-TR. 2000.
• Lan K., Demets D. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659—63.[Abstract/Free Full Text]
• O'Brien PC, Fleming TR A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549—56.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Pampallona S., Tsiatis A., Kim K. Interim monitoring of group sequential trials using spending functions for Type I and Type II error probabilities. Drug Information J 2001; 35: 1113—21.[Web of Science]
• Bland JM, Altman DG Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; i: 307—10.
• Division of AIDS Toxicity Table for Grading Severity of Pediatric (>3 months of Age) Adverse Experiences, www.niaid.nih.gov/dmid/clinresearch/DMIDpedtox.doc
• PACTG Adherence Questionnaire, www.fstrf.org/qol/peds/pedadhere.html
• United States Department of Health, Education and Welfare. Ten-state nutrition survey in the United States 1968—1970. 1972, Centers for Disease Control, Atlanta.
• Genant HK, Grampp S., Gluer CC, et al. Universal standardization for dual x-ray absorptiometry: patient and phantom cross-calibrations results. J Bone Mineral Res 1995; 9(10): 1503—14.[Web of Science]
• Interferon Plus Ribavirin Approved for First-Line Treatment of Hepatitis C, in Antiviral Agents Bulletin. 1998; 354.
• Landgraf JM, Abetz L., Ware JE The CHQ user's manual. The Health Institute, New England Medical Center, Boston, 1996.
• Gioia GA, Isquith PK, Guy SC, Kenworthy L. Behavior rating inventory of executive function., in Psychological Assessment Resources. 2000, Odessa.
• Achenbach TM, Rescorla LA Manual for the ASEBA school-age forms & profiles. University of Vermont, Research Center for Children, Youth, and Families, Burlington, 2001.
• Achenbach TM, Rescorla LA Manual for ASEBA Adult Forms and Profiles. Univ. of Vermont, Research Center for Children, Youth, and Families, Burlington, 2003.
• Kazak AE, Rourke MT, Crump TA In Roberts MC. (Ed). Families and other systems in pediatric psychology., 2003, pp. 159—175.
• Ware JE, Snow KK, Kosinski M., Gandek B. SF-36 health survey: manual and interpretation guide. Boston, The Health Institute, 1993.
• Hammad TA, Oaughren T., Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006; 63(3): 3329.
• Wietzke-Braun P., Meier V., Neubauer-Saile K., et al. Treatment of genotype 2 and 3 chronic hepatitis C virus infected patients. World J Gastroenterol 2005; 11(39): 6188—92.[Medline] [Order article via Infotrieve]
• Ellis KJ, Shypailo RJ, Pratt JA, Pond WG Accuracy of dual-energy x-ray absorptiometry for body-composition measurements in children. Am J Clin Nutr 1994; 60(5): 660—65.[Abstract/Free Full Text]

Clinical Trials, Vol. 4, No. 6, 661-673 (2007)
DOI: 10.1177/1740774507085445


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Murray, K. F. Search for Related Content PubMed PubMed Citation Articles by Murray, K. F. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB RIBAVIRIN Social Bookmarking                         What's this?